Trial Profile
Phase 2 Study of Efficacy and Safety of rhGH (Jintropin) in Pediatric Participants With ISS (Idiopathic Short Stature): a 52-week Multicenter, Open-label, Randomized, Negative Controlled Study Followed by a 52-week Open-label Period
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Short stature
- Focus Therapeutic Use
- Sponsors GeneScience Pharmaceuticals
- 24 Aug 2018 New trial record